Stockwatch: An Ultimate Answer To A Drug Pricing Question
This article was originally published in Scrip
Executive Summary
Last week was one of those weeks that makes you grateful that the stock markets close for the weekend. While the preparations and arrival of Pope Francis brought much of New York's Fifth Avenue and its surrounds to a standstill as Thursday wore on, it was a shame that his presence in the city could not have had the same effect on the stock markets based there.
You may also be interested in...
Stockwatch: Hopes For Fireworks But Expectations For Goldilocks
With the 38th J.P. Morgan Healthcare conference about to start in San Francisco, expectations in the investment community are naturally high. This is after a year when the NASDAQ Biotech Index approached its 2015 all-time high, fueled by the acquisitions of biotech companies by pharma companies.
Time Is Money: Is There A Better Way To Value Asset Duration In Biopharma Deal-Making?
Time is the least considered driver of asset valuations in life sciences – and may be a factor behind the low level of M&A deals so far this year. ICON’s Andy Smith provides some advice to the C-suite and business development managers on strategies to clarify the duration aspect in risk-sensitive transaction negotiations.
Stockwatch: Alexion, United Therapeutics, Intercept And "Alternative Facts"
Mid-cap biotech companies Alexion and United Therapeutics both missed fourth-quarter sales expectations and although Intercept beat analysts' estimates with $13.4m in sales, does that justify a $3bn valuation?
Need a specific report? 1000+ reports available
Buy Reports